-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the Fierce Pharma website released a list of the top 20 global pharmaceutical companies by revenue in 2020.
In the context of the global pandemic of the new crown epidemic, the ranking changes of pharmaceutical giants have attracted more and more attention.
Looking specifically at the top ten pharmaceutical companies, compared with the 2019 list, it can be found that the revenue ranking of pharmaceutical companies in 2020 has undergone a major reshuffle.
In the context of the global pandemic of the new crown epidemic, the ranking changes of pharmaceutical giants have attracted more and more attention.
Looking specifically at the top ten pharmaceutical companies, compared with the 2019 list, it can be found that the revenue ranking of pharmaceutical companies in 2020 has undergone a major reshuffle.
Among them, Pfizer, which completed the divestiture of the generic drug business Upjohn, fell 5 places to 8th place; and thanks to the acquisition of Allergan, AbbVie rose 3 places Ranking, successfully ranked among the top 5; also due to the acquisition of Celgene, Bristol-Myers Squibb (BMS) climbed 4 rankings and successfully entered the echelon of the top ten pharmaceutical companies; in many cases the impact of super mergers that reshaped the competitive landscape of the industry In 2019, Bayer, which was originally ranked at the bottom, fell out of the top ten this time.
Top ten pharmaceutical companies by sales revenue in 2020
(Source: FiecePharma)
Johnson & Johnson and Roche are still in the top two
There is no doubt that it is Johnson & Johnson that continues to win the championship.
Under the influence of the new crown epidemic, the company's sales revenue in 2020 is basically the same as in 2019, with a year-on-year increase of only 0.
6% to US$82.
6 billion.
However, it is worth noting that Johnson & Johnson's pharmaceutical sector performed strongly, with sales increasing by 8%, reaching US$45.
6 billion, pressing down on consumer healthcare , which grew by only 1.
1%, and medical equipment, which fell by 11.
6%.
Under the influence of the new crown epidemic, the company's sales revenue in 2020 is basically the same as in 2019, with a year-on-year increase of only 0.
6% to US$82.
6 billion.
However, it is worth noting that Johnson & Johnson's pharmaceutical sector performed strongly, with sales increasing by 8%, reaching US$45.
6 billion, pressing down on consumer healthcare , which grew by only 1.
1%, and medical equipment, which fell by 11.
6%.
Specific to the pharmaceutical sector, the new anti-inflammatory drug Stelara is still Johnson's best-selling drug, with sales reaching $7.
7 billion in 2020, achieving a 21% increase.
In terms of sales growth, the other two drugs from Johnson & Johnson are at the forefront: the psoriasis drug Tremfya (Tremfya) increased by 33% to reach 1.
35 billion US dollars; the anti-cancer drug dalatabine ( Darzalex) grew by 40% to $4.
2 billion.
At the same time, Johnson & Johnson's drug plight in a period of market decline is also deepening.
As the competition for biosimilar drugs has continued into the third year, sales of the anti-inflammatory drug Infliximab (Remicade) continue to decline by 14%, leaving only US$3.
75 billion; and also because of the emergence of lower-priced generic drugs, prostate cancer The drug Zytiga is losing market dominance, with sales falling 11.
6% year-on-year.
7 billion in 2020, achieving a 21% increase.
In terms of sales growth, the other two drugs from Johnson & Johnson are at the forefront: the psoriasis drug Tremfya (Tremfya) increased by 33% to reach 1.
35 billion US dollars; the anti-cancer drug dalatabine ( Darzalex) grew by 40% to $4.
2 billion.
At the same time, Johnson & Johnson's drug plight in a period of market decline is also deepening.
As the competition for biosimilar drugs has continued into the third year, sales of the anti-inflammatory drug Infliximab (Remicade) continue to decline by 14%, leaving only US$3.
75 billion; and also because of the emergence of lower-priced generic drugs, prostate cancer The drug Zytiga is losing market dominance, with sales falling 11.
6% year-on-year.
Roche still follows Johnson & Johnson as the "Runner-up" in revenue.
As the "troika" of Roche's tumor pipeline, rituximab (Rituxan), bevacizumab (Avastin) and trastuzumab (Herceptin) will be the first in 2020 to officially fight against biological similarities approved in the United States.
Medicine, but its impact exceeds most people’s expectations.
Officially disclosed data show that as of the end of 2020, Roche's global losses of 5.
7 billion Swiss francs due to biosimilar drugs, including 5.
05 billion Swiss francs from the United States, the European Union and Japan.
As the "troika" of Roche's tumor pipeline, rituximab (Rituxan), bevacizumab (Avastin) and trastuzumab (Herceptin) will be the first in 2020 to officially fight against biological similarities approved in the United States.
Medicine, but its impact exceeds most people’s expectations.
Officially disclosed data show that as of the end of 2020, Roche's global losses of 5.
7 billion Swiss francs due to biosimilar drugs, including 5.
05 billion Swiss francs from the United States, the European Union and Japan.
However, if you lose the East, you will receive the mulberry.
Starting from the third quarter of 2020, the multiple sclerosis drug Ocrevus has become Roche’s best-selling new drug, with annual sales reaching 4.
48 billion Swiss francs, but the 24% year-on-year growth rate is obviously lower than the 57% growth rate in 2019.
Slow down, lower than industry expectations.
In addition, the PD-L1 inhibitor Tecentriq is another key growth engine for Roche.
With 55% sales growth, it contributed 2.
74 billion Swiss francs in revenue to Roche.
The drug also achieved multiple milestones last year, including the newly diagnosed non-small cell lung cancer approved in the United States and the combination with bevacizumab for indications such as previously untreated liver cancer.
The market has great potential in the future.
Starting from the third quarter of 2020, the multiple sclerosis drug Ocrevus has become Roche’s best-selling new drug, with annual sales reaching 4.
48 billion Swiss francs, but the 24% year-on-year growth rate is obviously lower than the 57% growth rate in 2019.
Slow down, lower than industry expectations.
In addition, the PD-L1 inhibitor Tecentriq is another key growth engine for Roche.
With 55% sales growth, it contributed 2.
74 billion Swiss francs in revenue to Roche.
The drug also achieved multiple milestones last year, including the newly diagnosed non-small cell lung cancer approved in the United States and the combination with bevacizumab for indications such as previously untreated liver cancer.
The market has great potential in the future.
Super M&A becomes AbbVie, BMS booster
AbbVie’s 38% revenue growth is shocking at first glance, but behind this strong performance there is a simple explanation, that is, super mergers and acquisitions.
In May of last year, AbbVie completed the acquisition of Allergan at a "sky price" of $63 billion.
In fact, the product portfolio inherited from this Irish drugmaker contributed a lot to AbbVie’s revenue growth of US$12.
53 billion, which also made its total revenue ranking directly from the original 8th to the 5th.
In May of last year, AbbVie completed the acquisition of Allergan at a "sky price" of $63 billion.
In fact, the product portfolio inherited from this Irish drugmaker contributed a lot to AbbVie’s revenue growth of US$12.
53 billion, which also made its total revenue ranking directly from the original 8th to the 5th.
Under AbbVie's leadership, Allergan's original pipeline products, including botulinum toxin and depression drug Vraylar, have given new vitality.
In less than eight months, Vraylar's revenue of US$951 million surpassed its annual revenue of US$858 million in Allergan in 2019.
However, the field of immunology is still an important livelihood of AbbVie.
Although the "blockbuster" adalimumab sales have no longer peaked since 2019, it still achieved a 3.
5% growth rebound last year, reaching 19.
8 billion US dollars.
.
At the same time, AbbVie’s "young offspring" in the treatment field has also begun to work hard.
The sales of Skyrizi for the treatment of plaque psoriasis reached 1.
6 billion US dollars last year, and the sales of Rinvoq for the treatment of rheumatoid arthritis.
Reached 730 million US dollars, showing the potential of the ultimate substitute.
In less than eight months, Vraylar's revenue of US$951 million surpassed its annual revenue of US$858 million in Allergan in 2019.
However, the field of immunology is still an important livelihood of AbbVie.
Although the "blockbuster" adalimumab sales have no longer peaked since 2019, it still achieved a 3.
5% growth rebound last year, reaching 19.
8 billion US dollars.
.
At the same time, AbbVie’s "young offspring" in the treatment field has also begun to work hard.
The sales of Skyrizi for the treatment of plaque psoriasis reached 1.
6 billion US dollars last year, and the sales of Rinvoq for the treatment of rheumatoid arthritis.
Reached 730 million US dollars, showing the potential of the ultimate substitute.
Also benefiting from the super merger and acquisition is BMS.
This huge merger of up to 74 billion US dollars helped it climb 4 places and successfully entered the echelon of the top ten pharmaceutical companies.
Specifically, Xinji's annual sales contributed to a 63% increase in BMS's overall revenue.
Among them, the biggest "booster" for revenue growth is Xinji's blockbuster anti-cancer drug Revlimid.
Last year's sales reached 12.
1 billion U.
S.
dollars, an increase of 12% year-on-year.
In addition, the products in BMS's own pipeline also performed well.
Since the new crown can be reduced in patients with stroke and heart risk of disease onset, blood thinner apixaban (Eliquis) sales increased 16 percent to $ 9.
2 billion.
In addition, the anti-inflammatory drug Abatacept (Orencia) and the leukemia drug Dasatinib (Sprycel) also achieved US$3.
2 billion and US$2.
1 billion respectively.
This huge merger of up to 74 billion US dollars helped it climb 4 places and successfully entered the echelon of the top ten pharmaceutical companies.
Specifically, Xinji's annual sales contributed to a 63% increase in BMS's overall revenue.
Among them, the biggest "booster" for revenue growth is Xinji's blockbuster anti-cancer drug Revlimid.
Last year's sales reached 12.
1 billion U.
S.
dollars, an increase of 12% year-on-year.
In addition, the products in BMS's own pipeline also performed well.
Since the new crown can be reduced in patients with stroke and heart risk of disease onset, blood thinner apixaban (Eliquis) sales increased 16 percent to $ 9.
2 billion.
In addition, the anti-inflammatory drug Abatacept (Orencia) and the leukemia drug Dasatinib (Sprycel) also achieved US$3.
2 billion and US$2.
1 billion respectively.
However, some of the main BMS drugs are also in trouble.
As PD-1 inhibitors continue to face fierce competition from rival Merck’s Keytruda, Opdivo’s sales fell 3% to US$7 billion.
At the same time, the combination of Opdivo and chemotherapy in the treatment of non-squamous non-small cell lung cancer is not better than the failure of chemotherapy alone, and it is also deepening investor concerns.
However, some analysts pointed out that the US FDA last year also approved two indications for the combined use of Opdivo and Yervoy, another immuno- oncology drug from BMS .
Opdivo should still have room for growth.
As PD-1 inhibitors continue to face fierce competition from rival Merck’s Keytruda, Opdivo’s sales fell 3% to US$7 billion.
At the same time, the combination of Opdivo and chemotherapy in the treatment of non-squamous non-small cell lung cancer is not better than the failure of chemotherapy alone, and it is also deepening investor concerns.
However, some analysts pointed out that the US FDA last year also approved two indications for the combined use of Opdivo and Yervoy, another immuno- oncology drug from BMS .
Opdivo should still have room for growth.
Pfizer and Sanofi decline in rankings
Due to the divestiture of the generic drug business Puqiang, Pfizer dropped from third place last year to eighth in the top 20 list announced by Fierce Pharma.
However, if you exclude the performance of Puqiang, Pfizer's total revenue of $41.
9 billion in 2020 will still achieve a year-on-year growth of 2%.
However, if you exclude the performance of Puqiang, Pfizer's total revenue of $41.
9 billion in 2020 will still achieve a year-on-year growth of 2%.
From a product perspective, Xtandi, a prostate cancer treatment drug, is undoubtedly Pfizer’s fastest-growing variety, with a year-on-year increase of 22% and sales of US$1.
02 billion.
In addition, the blood thinner apixaban (Eliquis) also increased by 17% to reach 4.
95 billion U.
S.
dollars, and the breast cancer drug Ibrance (Ibrance) achieved a 9% increase, with annual sales of 5.
39 billion U.
S.
dollars.
However, the anti-inflammatory drug Enbrel performed poorly, with sales falling 21% to US$1.
35 billion; sales of the smoking cessation drug Chantix also fell 17% to US$919 million.
Pfizer predicts that its new crown vaccine sales will reach about 15 billion US dollars this year, which will increase its overall sales revenue expectations.
02 billion.
In addition, the blood thinner apixaban (Eliquis) also increased by 17% to reach 4.
95 billion U.
S.
dollars, and the breast cancer drug Ibrance (Ibrance) achieved a 9% increase, with annual sales of 5.
39 billion U.
S.
dollars.
However, the anti-inflammatory drug Enbrel performed poorly, with sales falling 21% to US$1.
35 billion; sales of the smoking cessation drug Chantix also fell 17% to US$919 million.
Pfizer predicts that its new crown vaccine sales will reach about 15 billion US dollars this year, which will increase its overall sales revenue expectations.
Among the ranking changes caused by super mergers and acquisitions, Sanofi also showed a significant "decline".
In fact, in the first full year of the new CE0 Paul Hudson (Paul Hudson), Sanofi handed over a dazzling report card.
In 2020, overall sales increased by 3.
3% to 36 billion euros.
At the same time, the sales volume of various products broke new highs.
In fact, in the first full year of the new CE0 Paul Hudson (Paul Hudson), Sanofi handed over a dazzling report card.
In 2020, overall sales increased by 3.
3% to 36 billion euros.
At the same time, the sales volume of various products broke new highs.
Under the new crown epidemic, Sanofi's blockbuster atopic dermatitis treatment Dupixent achieved sales of more than US$1 billion in the third quarter alone, a year-on-year increase of 69%.
The total revenue for the whole year of 2020 will be even greater.
It reached 3.
5 billion euros.
Driven by the successive launches of Sarclisa and Libtayo and the growth of old drugs, Sanofi's anti-tumor drug sales increased by 27% to 798 million euros.
However, on the other hand, the sales of diabetes and cardiovascular drugs, which used to have a significant share in Sanofi, fell again.
Diabetes sales fell by 4.
8% to 4.
7 billion euros, and the cardiovascular and traditional drugs business revenue fell by 8.
8% to 10 billion.
EUR.
The total revenue for the whole year of 2020 will be even greater.
It reached 3.
5 billion euros.
Driven by the successive launches of Sarclisa and Libtayo and the growth of old drugs, Sanofi's anti-tumor drug sales increased by 27% to 798 million euros.
However, on the other hand, the sales of diabetes and cardiovascular drugs, which used to have a significant share in Sanofi, fell again.
Diabetes sales fell by 4.
8% to 4.
7 billion euros, and the cardiovascular and traditional drugs business revenue fell by 8.
8% to 10 billion.
EUR.
A few days ago, the Fierce Pharma website released a list of the top 20 global pharmaceutical companies by revenue in 2020.
In the context of the global pandemic of the new crown epidemic, the ranking changes of pharmaceutical giants have attracted more and more attention.
Looking specifically at the top ten pharmaceutical companies, compared with the 2019 list, it can be found that the revenue ranking of pharmaceutical companies in 2020 has undergone a major reshuffle.
In the context of the global pandemic of the new crown epidemic, the ranking changes of pharmaceutical giants have attracted more and more attention.
Looking specifically at the top ten pharmaceutical companies, compared with the 2019 list, it can be found that the revenue ranking of pharmaceutical companies in 2020 has undergone a major reshuffle.
Among them, Pfizer, which completed the divestiture of the generic drug business Upjohn, fell 5 places to 8th place; and thanks to the acquisition of Allergan, AbbVie rose 3 places Ranking, successfully ranked among the top 5; also due to the acquisition of Celgene, Bristol-Myers Squibb (BMS) climbed 4 rankings and successfully entered the echelon of the top ten pharmaceutical companies; in many cases the impact of super mergers that reshaped the competitive landscape of the industry In 2019, Bayer, which was originally ranked at the bottom, fell out of the top ten this time.
Top ten pharmaceutical companies by sales revenue in 2020
(Source: FiecePharma)
Johnson & Johnson and Roche are still in the top two
There is no doubt that it is Johnson & Johnson that continues to win the championship.
Under the influence of the new crown epidemic, the company's sales revenue in 2020 is basically the same as in 2019, with a year-on-year increase of only 0.
6% to US$82.
6 billion.
However, it is worth noting that Johnson & Johnson's pharmaceutical sector performed strongly, with sales increasing by 8%, reaching US$45.
6 billion, pressing down on consumer healthcare , which grew by only 1.
1%, and medical equipment, which fell by 11.
6%.
Under the influence of the new crown epidemic, the company's sales revenue in 2020 is basically the same as in 2019, with a year-on-year increase of only 0.
6% to US$82.
6 billion.
However, it is worth noting that Johnson & Johnson's pharmaceutical sector performed strongly, with sales increasing by 8%, reaching US$45.
6 billion, pressing down on consumer healthcare , which grew by only 1.
1%, and medical equipment, which fell by 11.
6%.
Specific to the pharmaceutical sector, the new anti-inflammatory drug Stelara is still Johnson's best-selling drug, with sales reaching $7.
7 billion in 2020, achieving a 21% increase.
In terms of sales growth, the other two drugs from Johnson & Johnson are at the forefront: the psoriasis drug Tremfya (Tremfya) increased by 33% to reach 1.
35 billion US dollars; the anti-cancer drug dalatabine ( Darzalex) grew by 40% to $4.
2 billion.
At the same time, Johnson & Johnson's drug plight in a period of market decline is also deepening.
As the competition for biosimilar drugs has continued into the third year, sales of the anti-inflammatory drug Infliximab (Remicade) continue to decline by 14%, leaving only US$3.
75 billion; and also because of the emergence of lower-priced generic drugs, prostate cancer The drug Zytiga is losing market dominance, with sales falling 11.
6% year-on-year.
7 billion in 2020, achieving a 21% increase.
In terms of sales growth, the other two drugs from Johnson & Johnson are at the forefront: the psoriasis drug Tremfya (Tremfya) increased by 33% to reach 1.
35 billion US dollars; the anti-cancer drug dalatabine ( Darzalex) grew by 40% to $4.
2 billion.
At the same time, Johnson & Johnson's drug plight in a period of market decline is also deepening.
As the competition for biosimilar drugs has continued into the third year, sales of the anti-inflammatory drug Infliximab (Remicade) continue to decline by 14%, leaving only US$3.
75 billion; and also because of the emergence of lower-priced generic drugs, prostate cancer The drug Zytiga is losing market dominance, with sales falling 11.
6% year-on-year.
Roche still follows Johnson & Johnson as the "Runner-up" in revenue.
As the "troika" of Roche's tumor pipeline, rituximab (Rituxan), bevacizumab (Avastin) and trastuzumab (Herceptin) will be the first in 2020 to officially fight against biological similarities approved in the United States.
Medicine, but its impact exceeds most people’s expectations.
Officially disclosed data show that as of the end of 2020, Roche's global losses of 5.
7 billion Swiss francs due to biosimilar drugs, including 5.
05 billion Swiss francs from the United States, the European Union and Japan.
As the "troika" of Roche's tumor pipeline, rituximab (Rituxan), bevacizumab (Avastin) and trastuzumab (Herceptin) will be the first in 2020 to officially fight against biological similarities approved in the United States.
Medicine, but its impact exceeds most people’s expectations.
Officially disclosed data show that as of the end of 2020, Roche's global losses of 5.
7 billion Swiss francs due to biosimilar drugs, including 5.
05 billion Swiss francs from the United States, the European Union and Japan.
However, if you lose the East, you will receive the mulberry.
Starting from the third quarter of 2020, the multiple sclerosis drug Ocrevus has become Roche’s best-selling new drug, with annual sales reaching 4.
48 billion Swiss francs, but the 24% year-on-year growth rate is obviously lower than the 57% growth rate in 2019.
Slow down, lower than industry expectations.
In addition, the PD-L1 inhibitor Tecentriq is another key growth engine for Roche.
With 55% sales growth, it contributed 2.
74 billion Swiss francs in revenue to Roche.
The drug also achieved multiple milestones last year, including the newly diagnosed non-small cell lung cancer approved in the United States and the combination with bevacizumab for indications such as previously untreated liver cancer.
The market has great potential in the future.
Starting from the third quarter of 2020, the multiple sclerosis drug Ocrevus has become Roche’s best-selling new drug, with annual sales reaching 4.
48 billion Swiss francs, but the 24% year-on-year growth rate is obviously lower than the 57% growth rate in 2019.
Slow down, lower than industry expectations.
In addition, the PD-L1 inhibitor Tecentriq is another key growth engine for Roche.
With 55% sales growth, it contributed 2.
74 billion Swiss francs in revenue to Roche.
The drug also achieved multiple milestones last year, including the newly diagnosed non-small cell lung cancer approved in the United States and the combination with bevacizumab for indications such as previously untreated liver cancer.
The market has great potential in the future.
Super M&A becomes AbbVie, BMS booster
AbbVie’s 38% revenue growth is shocking at first glance, but behind this strong performance there is a simple explanation, that is, super mergers and acquisitions.
In May of last year, AbbVie completed the acquisition of Allergan at a "sky price" of $63 billion.
In fact, the product portfolio inherited from this Irish drugmaker contributed a lot to AbbVie’s revenue growth of US$12.
53 billion, which also made its total revenue ranking directly from the original 8th to the 5th.
In May of last year, AbbVie completed the acquisition of Allergan at a "sky price" of $63 billion.
In fact, the product portfolio inherited from this Irish drugmaker contributed a lot to AbbVie’s revenue growth of US$12.
53 billion, which also made its total revenue ranking directly from the original 8th to the 5th.
Under AbbVie's leadership, Allergan's original pipeline products, including botulinum toxin and depression drug Vraylar, have given new vitality.
In less than eight months, Vraylar's revenue of US$951 million surpassed its annual revenue of US$858 million in Allergan in 2019.
However, the field of immunology is still an important livelihood of AbbVie.
Although the "blockbuster" adalimumab sales have no longer peaked since 2019, it still achieved a 3.
5% growth rebound last year, reaching 19.
8 billion US dollars.
.
At the same time, AbbVie’s "young offspring" in the treatment field has also begun to work hard.
The sales of Skyrizi for the treatment of plaque psoriasis reached 1.
6 billion US dollars last year, and the sales of Rinvoq for the treatment of rheumatoid arthritis.
Reached 730 million US dollars, showing the potential of the ultimate substitute.
In less than eight months, Vraylar's revenue of US$951 million surpassed its annual revenue of US$858 million in Allergan in 2019.
However, the field of immunology is still an important livelihood of AbbVie.
Although the "blockbuster" adalimumab sales have no longer peaked since 2019, it still achieved a 3.
5% growth rebound last year, reaching 19.
8 billion US dollars.
.
At the same time, AbbVie’s "young offspring" in the treatment field has also begun to work hard.
The sales of Skyrizi for the treatment of plaque psoriasis reached 1.
6 billion US dollars last year, and the sales of Rinvoq for the treatment of rheumatoid arthritis.
Reached 730 million US dollars, showing the potential of the ultimate substitute.
Also benefiting from the super merger and acquisition is BMS.
This huge merger of up to 74 billion US dollars helped it climb 4 places and successfully entered the echelon of the top ten pharmaceutical companies.
Specifically, Xinji's annual sales contributed to a 63% increase in BMS's overall revenue.
Among them, the biggest "booster" for revenue growth is Xinji's blockbuster anti-cancer drug Revlimid.
Last year's sales reached 12.
1 billion U.
S.
dollars, an increase of 12% year-on-year.
In addition, the products in BMS's own pipeline also performed well.
Since the new crown can be reduced in patients with stroke and heart risk of disease onset, blood thinner apixaban (Eliquis) sales increased 16 percent to $ 9.
2 billion.
In addition, the anti-inflammatory drug Abatacept (Orencia) and the leukemia drug Dasatinib (Sprycel) also achieved US$3.
2 billion and US$2.
1 billion respectively.
This huge merger of up to 74 billion US dollars helped it climb 4 places and successfully entered the echelon of the top ten pharmaceutical companies.
Specifically, Xinji's annual sales contributed to a 63% increase in BMS's overall revenue.
Among them, the biggest "booster" for revenue growth is Xinji's blockbuster anti-cancer drug Revlimid.
Last year's sales reached 12.
1 billion U.
S.
dollars, an increase of 12% year-on-year.
In addition, the products in BMS's own pipeline also performed well.
Since the new crown can be reduced in patients with stroke and heart risk of disease onset, blood thinner apixaban (Eliquis) sales increased 16 percent to $ 9.
2 billion.
In addition, the anti-inflammatory drug Abatacept (Orencia) and the leukemia drug Dasatinib (Sprycel) also achieved US$3.
2 billion and US$2.
1 billion respectively.
However, some of the main BMS drugs are also in trouble.
As PD-1 inhibitors continue to face fierce competition from rival Merck’s Keytruda, Opdivo’s sales fell 3% to US$7 billion.
At the same time, the combination of Opdivo and chemotherapy in the treatment of non-squamous non-small cell lung cancer is not better than the failure of chemotherapy alone, and it is also deepening investor concerns.
However, some analysts pointed out that the US FDA last year also approved two indications for the combined use of Opdivo and Yervoy, another immuno- oncology drug from BMS .
Opdivo should still have room for growth.
As PD-1 inhibitors continue to face fierce competition from rival Merck’s Keytruda, Opdivo’s sales fell 3% to US$7 billion.
At the same time, the combination of Opdivo and chemotherapy in the treatment of non-squamous non-small cell lung cancer is not better than the failure of chemotherapy alone, and it is also deepening investor concerns.
However, some analysts pointed out that the US FDA last year also approved two indications for the combined use of Opdivo and Yervoy, another immuno- oncology drug from BMS .
Opdivo should still have room for growth.
Pfizer and Sanofi decline in rankings
Due to the divestiture of the generic drug business Puqiang, Pfizer dropped from third place last year to eighth in the top 20 list announced by Fierce Pharma.
However, if you exclude the performance of Puqiang, Pfizer's total revenue of $41.
9 billion in 2020 will still achieve a year-on-year growth of 2%.
However, if you exclude the performance of Puqiang, Pfizer's total revenue of $41.
9 billion in 2020 will still achieve a year-on-year growth of 2%.
From a product perspective, Xtandi, a prostate cancer treatment drug, is undoubtedly Pfizer’s fastest-growing variety, with a year-on-year increase of 22% and sales of US$1.
02 billion.
In addition, the blood thinner apixaban (Eliquis) also increased by 17% to reach 4.
95 billion U.
S.
dollars, and the breast cancer drug Ibrance (Ibrance) achieved a 9% increase, with annual sales of 5.
39 billion U.
S.
dollars.
However, the anti-inflammatory drug Enbrel performed poorly, with sales falling 21% to US$1.
35 billion; sales of the smoking cessation drug Chantix also fell 17% to US$919 million.
Pfizer predicts that its new crown vaccine sales will reach about 15 billion US dollars this year, which will increase its overall sales revenue expectations.
02 billion.
In addition, the blood thinner apixaban (Eliquis) also increased by 17% to reach 4.
95 billion U.
S.
dollars, and the breast cancer drug Ibrance (Ibrance) achieved a 9% increase, with annual sales of 5.
39 billion U.
S.
dollars.
However, the anti-inflammatory drug Enbrel performed poorly, with sales falling 21% to US$1.
35 billion; sales of the smoking cessation drug Chantix also fell 17% to US$919 million.
Pfizer predicts that its new crown vaccine sales will reach about 15 billion US dollars this year, which will increase its overall sales revenue expectations.
Among the ranking changes caused by super mergers and acquisitions, Sanofi also showed a significant "decline".
In fact, in the first full year of the new CE0 Paul Hudson (Paul Hudson), Sanofi handed over a dazzling report card.
In 2020, overall sales increased by 3.
3% to 36 billion euros.
At the same time, the sales volume of various products broke new highs.
In fact, in the first full year of the new CE0 Paul Hudson (Paul Hudson), Sanofi handed over a dazzling report card.
In 2020, overall sales increased by 3.
3% to 36 billion euros.
At the same time, the sales volume of various products broke new highs.
Under the new crown epidemic, Sanofi's blockbuster atopic dermatitis treatment Dupixent achieved sales of more than US$1 billion in the third quarter alone, a year-on-year increase of 69%.
The total revenue for the whole year of 2020 will be even greater.
It reached 3.
5 billion euros.
Driven by the successive launches of Sarclisa and Libtayo and the growth of old drugs, Sanofi's anti-tumor drug sales increased by 27% to 798 million euros.
However, on the other hand, the sales of diabetes and cardiovascular drugs, which used to have a significant share in Sanofi, fell again.
Diabetes sales fell by 4.
8% to 4.
7 billion euros, and the cardiovascular and traditional drugs business revenue fell by 8.
8% to 10 billion.
EUR.
The total revenue for the whole year of 2020 will be even greater.
It reached 3.
5 billion euros.
Driven by the successive launches of Sarclisa and Libtayo and the growth of old drugs, Sanofi's anti-tumor drug sales increased by 27% to 798 million euros.
However, on the other hand, the sales of diabetes and cardiovascular drugs, which used to have a significant share in Sanofi, fell again.
Diabetes sales fell by 4.
8% to 4.
7 billion euros, and the cardiovascular and traditional drugs business revenue fell by 8.
8% to 10 billion.
EUR.
A few days ago, the Fierce Pharma website released a list of the top 20 global pharmaceutical companies by revenue in 2020.
In the context of the global pandemic of the new crown epidemic, the ranking changes of pharmaceutical giants have attracted more and more attention.
Looking specifically at the top ten pharmaceutical companies, compared with the 2019 list, it can be found that the revenue ranking of pharmaceutical companies in 2020 has undergone a major reshuffle.
In the context of the global pandemic of the new crown epidemic, the ranking changes of pharmaceutical giants have attracted more and more attention.
Looking specifically at the top ten pharmaceutical companies, compared with the 2019 list, it can be found that the revenue ranking of pharmaceutical companies in 2020 has undergone a major reshuffle.
Among them, Pfizer, which completed the divestiture of the generic drug business Upjohn, fell 5 places to 8th place; and thanks to the acquisition of Allergan, AbbVie rose 3 places Ranking, successfully ranked among the top 5; also due to the acquisition of Celgene, Bristol-Myers Squibb (BMS) climbed 4 rankings and successfully entered the echelon of the top ten pharmaceutical companies; in many cases the impact of super mergers that reshaped the competitive landscape of the industry In 2019, Bayer, which was originally ranked at the bottom, fell out of the top ten this time.
Top ten pharmaceutical companies by sales revenue in 2020
(Source: FiecePharma)
Johnson & Johnson and Roche are still in the top two
Johnson & Johnson and Roche are still in the top two There is no doubt that it is Johnson & Johnson that continues to win the championship.
Under the influence of the new crown epidemic, the company's sales revenue in 2020 is basically the same as in 2019, with a year-on-year increase of only 0.
6% to US$82.
6 billion.
However, it is worth noting that Johnson & Johnson's pharmaceutical sector performed strongly, with sales increasing by 8%, reaching US$45.
6 billion, pressing down on consumer healthcare , which grew by only 1.
1%, and medical equipment, which fell by 11.
6%.
Health Health CareUnder the influence of the new crown epidemic, the company's sales revenue in 2020 is basically the same as in 2019, with a year-on-year increase of only 0.
6% to US$82.
6 billion.
However, it is worth noting that Johnson & Johnson's pharmaceutical sector performed strongly, with sales increasing by 8%, reaching US$45.
6 billion, pressing down on consumer healthcare , which grew by only 1.
1%, and medical equipment, which fell by 11.
6%.
Specific to the pharmaceutical sector, the new anti-inflammatory drug Stelara is still Johnson's best-selling drug, with sales reaching $7.
7 billion in 2020, achieving a 21% increase.
In terms of sales growth, the other two drugs from Johnson & Johnson are at the forefront: the psoriasis drug Tremfya (Tremfya) increased by 33% to reach 1.
35 billion US dollars; the anti-cancer drug dalatabine ( Darzalex) grew by 40% to $4.
2 billion.
At the same time, Johnson & Johnson's drug plight in a period of market decline is also deepening.
As the competition for biosimilar drugs has continued into the third year, sales of the anti-inflammatory drug Infliximab (Remicade) continue to decline by 14%, leaving only US$3.
75 billion; and also because of the emergence of lower-priced generic drugs, prostate cancer The drug Zytiga is losing market dominance, with sales falling 11.
6% year-on-year.
7 billion in 2020, achieving a 21% increase.
In terms of sales growth, the other two drugs from Johnson & Johnson are at the forefront: the psoriasis drug Tremfya (Tremfya) increased by 33% to reach 1.
35 billion US dollars; the anti-cancer drug dalatabine ( Darzalex) grew by 40% to $4.
2 billion.
At the same time, Johnson & Johnson's drug plight in a period of market decline is also deepening.
As the competition for biosimilar drugs has continued into the third year, sales of the anti-inflammatory drug Infliximab (Remicade) continue to decline by 14%, leaving only US$3.
75 billion; and also because of the emergence of lower-priced generic drugs, prostate cancer The drug Zytiga is losing market dominance, with sales falling 11.
6% year-on-year.
Roche still follows Johnson & Johnson as the "Runner-up" in revenue.
As the "troika" of Roche's tumor pipeline, rituximab (Rituxan), bevacizumab (Avastin) and trastuzumab (Herceptin) will be the first in 2020 to officially fight against biological similarities approved in the United States.
Medicine, but its impact exceeds most people’s expectations.
Officially disclosed data show that as of the end of 2020, Roche's global losses of 5.
7 billion Swiss francs due to biosimilar drugs, including 5.
05 billion Swiss francs from the United States, the European Union and Japan.
As the "troika" of Roche's tumor pipeline, rituximab (Rituxan), bevacizumab (Avastin) and trastuzumab (Herceptin) will be the first in 2020 to officially fight against biological similarities approved in the United States.
Medicine, but its impact exceeds most people’s expectations.
Officially disclosed data show that as of the end of 2020, Roche's global losses of 5.
7 billion Swiss francs due to biosimilar drugs, including 5.
05 billion Swiss francs from the United States, the European Union and Japan.
However, if you lose the East, you will receive the mulberry.
Starting from the third quarter of 2020, the multiple sclerosis drug Ocrevus has become Roche’s best-selling new drug, with annual sales reaching 4.
48 billion Swiss francs, but the 24% year-on-year growth rate is obviously lower than the 57% growth rate in 2019.
Slow down, lower than industry expectations.
In addition, the PD-L1 inhibitor Tecentriq is another key growth engine for Roche.
With 55% sales growth, it contributed 2.
74 billion Swiss francs in revenue to Roche.
The drug also achieved multiple milestones last year, including the newly diagnosed non-small cell lung cancer approved in the United States and the combination with bevacizumab for indications such as previously untreated liver cancer.
The market has great potential in the future.
Starting from the third quarter of 2020, the multiple sclerosis drug Ocrevus has become Roche’s best-selling new drug, with annual sales reaching 4.
48 billion Swiss francs, but the 24% year-on-year growth rate is obviously lower than the 57% growth rate in 2019.
Slow down, lower than industry expectations.
In addition, the PD-L1 inhibitor Tecentriq is another key growth engine for Roche.
With 55% sales growth, it contributed 2.
74 billion Swiss francs in revenue to Roche.
The drug also achieved multiple milestones last year, including the newly diagnosed non-small cell lung cancer approved in the United States and the combination with bevacizumab for indications such as previously untreated liver cancer.
The market has great potential in the future.
Super M&A becomes AbbVie, BMS booster
Super M&A becomes AbbVie, BMS booster AbbVie’s 38% revenue growth is shocking at first glance, but behind this strong performance there is a simple explanation, that is, super mergers and acquisitions.
In May of last year, AbbVie completed the acquisition of Allergan at a "sky price" of $63 billion.
In fact, the product portfolio inherited from this Irish drugmaker contributed a lot to AbbVie’s revenue growth of US$12.
53 billion, which also made its total revenue ranking directly from the original 8th to the 5th.
In May of last year, AbbVie completed the acquisition of Allergan at a "sky price" of $63 billion.
In fact, the product portfolio inherited from this Irish drugmaker contributed a lot to AbbVie’s revenue growth of US$12.
53 billion, which also made its total revenue ranking directly from the original 8th to the 5th.
Under AbbVie's leadership, Allergan's original pipeline products, including botulinum toxin and depression drug Vraylar, have given new vitality.
In less than eight months, Vraylar's revenue of US$951 million surpassed its annual revenue of US$858 million in Allergan in 2019.
However, the field of immunology is still an important livelihood of AbbVie.
Although the "blockbuster" adalimumab sales have no longer peaked since 2019, it still achieved a 3.
5% growth rebound last year, reaching 19.
8 billion US dollars.
.
At the same time, AbbVie’s "young offspring" in the treatment field has also begun to work hard.
The sales of Skyrizi for the treatment of plaque psoriasis reached 1.
6 billion US dollars last year, and the sales of Rinvoq for the treatment of rheumatoid arthritis.
Reached 730 million US dollars, showing the potential of the ultimate substitute.
In less than eight months, Vraylar's revenue of US$951 million surpassed its annual revenue of US$858 million in Allergan in 2019.
However, the field of immunology is still an important livelihood of AbbVie.
Although the "blockbuster" adalimumab sales have no longer peaked since 2019, it still achieved a 3.
5% growth rebound last year, reaching 19.
8 billion US dollars.
.
At the same time, AbbVie’s "young offspring" in the treatment field has also begun to work hard.
The sales of Skyrizi for the treatment of plaque psoriasis reached 1.
6 billion US dollars last year, and the sales of Rinvoq for the treatment of rheumatoid arthritis.
Reached 730 million US dollars, showing the potential of the ultimate substitute.
Also benefiting from the super merger and acquisition is BMS.
This huge merger of up to 74 billion US dollars helped it climb 4 places and successfully entered the echelon of the top ten pharmaceutical companies.
Specifically, Xinji's annual sales contributed to a 63% increase in BMS's overall revenue.
Among them, the biggest "booster" for revenue growth is Xinji's blockbuster anti-cancer drug Revlimid.
Last year's sales reached 12.
1 billion U.
S.
dollars, an increase of 12% year-on-year.
In addition, the products in BMS's own pipeline also performed well.
Since the new crown can be reduced in patients with stroke and heart risk of disease onset, blood thinner apixaban (Eliquis) sales increased 16 percent to $ 9.
2 billion.
In addition, the anti-inflammatory drug Abatacept (Orencia) and the leukemia drug Dasatinib (Sprycel) also achieved US$3.
2 billion and US$2.
1 billion respectively.
Heart, heart, heartThis huge merger of up to 74 billion US dollars helped it climb 4 places and successfully entered the echelon of the top ten pharmaceutical companies.
Specifically, Xinji's annual sales contributed to a 63% increase in BMS's overall revenue.
Among them, the biggest "booster" for revenue growth is Xinji's blockbuster anti-cancer drug Revlimid.
Last year's sales reached 12.
1 billion U.
S.
dollars, an increase of 12% year-on-year.
In addition, the products in BMS's own pipeline also performed well.
Since the new crown can be reduced in patients with stroke and heart risk of disease onset, blood thinner apixaban (Eliquis) sales increased 16 percent to $ 9.
2 billion.
In addition, the anti-inflammatory drug Abatacept (Orencia) and the leukemia drug Dasatinib (Sprycel) also achieved US$3.
2 billion and US$2.
1 billion respectively.
However, some of the main BMS drugs are also in trouble.
As PD-1 inhibitors continue to face fierce competition from rival Merck’s Keytruda, Opdivo’s sales fell 3% to US$7 billion.
At the same time, the combination of Opdivo and chemotherapy in the treatment of non-squamous non-small cell lung cancer is not better than the failure of chemotherapy alone, and it is also deepening investor concerns.
However, some analysts pointed out that the US FDA last year also approved two indications for the combined use of Opdivo and Yervoy, another immuno- oncology drug from BMS .
Opdivo should still have room for growth.
Tumor tumor tumorAs PD-1 inhibitors continue to face fierce competition from rival Merck’s Keytruda, Opdivo’s sales fell 3% to US$7 billion.
At the same time, the combination of Opdivo and chemotherapy in the treatment of non-squamous non-small cell lung cancer is not better than the failure of chemotherapy alone, and it is also deepening investor concerns.
However, some analysts pointed out that the US FDA last year also approved two indications for the combined use of Opdivo and Yervoy, another immuno- oncology drug from BMS .
Opdivo should still have room for growth.
Pfizer and Sanofi decline in rankings
Pfizer and Sanofi decline in rankings Due to the divestiture of the generic drug business Puqiang, Pfizer dropped from third place last year to eighth in the top 20 list announced by Fierce Pharma.
However, if you exclude the performance of Puqiang, Pfizer's total revenue of $41.
9 billion in 2020 will still achieve a year-on-year growth of 2%.
However, if you exclude the performance of Puqiang, Pfizer's total revenue of $41.
9 billion in 2020 will still achieve a year-on-year growth of 2%.
From a product perspective, Xtandi, a prostate cancer treatment drug, is undoubtedly Pfizer’s fastest-growing variety, with a year-on-year increase of 22% and sales of US$1.
02 billion.
In addition, the blood thinner apixaban (Eliquis) also increased by 17% to reach 4.
95 billion U.
S.
dollars, and the breast cancer drug Ibrance (Ibrance) achieved a 9% increase, with annual sales of 5.
39 billion U.
S.
dollars.
However, the anti-inflammatory drug Enbrel performed poorly, with sales falling 21% to US$1.
35 billion; sales of the smoking cessation drug Chantix also fell 17% to US$919 million.
Pfizer predicts that its new crown vaccine sales will reach about 15 billion US dollars this year, which will increase its overall sales revenue expectations.
02 billion.
In addition, the blood thinner apixaban (Eliquis) also increased by 17% to reach 4.
95 billion U.
S.
dollars, and the breast cancer drug Ibrance (Ibrance) achieved a 9% increase, with annual sales of 5.
39 billion U.
S.
dollars.
However, the anti-inflammatory drug Enbrel performed poorly, with sales falling 21% to US$1.
35 billion; sales of the smoking cessation drug Chantix also fell 17% to US$919 million.
Pfizer predicts that its new crown vaccine sales will reach about 15 billion US dollars this year, which will increase its overall sales revenue expectations.
Among the ranking changes caused by super mergers and acquisitions, Sanofi also showed a significant "decline".
In fact, in the first full year of the new CE0 Paul Hudson (Paul Hudson), Sanofi handed over a dazzling report card.
In 2020, overall sales increased by 3.
3% to 36 billion euros.
At the same time, the sales volume of various products broke new highs.
In fact, in the first full year of the new CE0 Paul Hudson (Paul Hudson), Sanofi handed over a dazzling report card.
In 2020, overall sales increased by 3.
3% to 36 billion euros.
At the same time, the sales volume of various products broke new highs.
Under the new crown epidemic, Sanofi's blockbuster atopic dermatitis treatment Dupixent achieved sales of more than US$1 billion in the third quarter alone, a year-on-year increase of 69%.
The total revenue for the whole year of 2020 will be even greater.
It reached 3.
5 billion euros.
Driven by the successive launches of Sarclisa and Libtayo and the growth of old drugs, Sanofi's anti-tumor drug sales increased by 27% to 798 million euros.
However, on the other hand, the sales of diabetes and cardiovascular drugs, which used to have a significant share in Sanofi, fell again.
Diabetes sales fell by 4.
8% to 4.
7 billion euros, and the cardiovascular and traditional drugs business revenue fell by 8.
8% to 10 billion.
EUR.
The total revenue for the whole year of 2020 will be even greater.
It reached 3.
5 billion euros.
Driven by the successive launches of Sarclisa and Libtayo and the growth of old drugs, Sanofi's anti-tumor drug sales increased by 27% to 798 million euros.
However, on the other hand, the sales of diabetes and cardiovascular drugs, which used to have a significant share in Sanofi, fell again.
Diabetes sales fell by 4.
8% to 4.
7 billion euros, and the cardiovascular and traditional drugs business revenue fell by 8.
8% to 10 billion.
EUR.
